[
  {
    "sentence": "The ability to pre‐emptively identify women at increased risk for breast cancer is constantly evolving, with an expanding and better‐defined patient pool eligible for chemoprevention, whereas management and risk reduction options are lagging (Fig 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Overall, leveraging the potent influence of progesterone and its effects on mammary stem/progenitors, an anti‐progestin approach for prevention offers promise (Fig 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Ulipristal acetate is a selective progesterone receptor modulator, and denosumab is an anti‐RANKL agent. (B) Schematic of key mitogenic paracrine effectors downstream of progesterone in the breast, some of which may prove effective as targets in future breast cancer chemoprevention strategies.Progesterone's paracrine effectors\nWe now know that progesterone acts upon the ER+PR+ cells, which orchestrates a surge of potent paracrine effectors that in turn stimulate proliferation of the ER−PR− progenitor populations (Lydon et al, 1995; Humphreys et al, 1997; Brisken et al, 1998; Joshi et al, 2012; summarized in Fig 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Proteomic landscapes of murine mammary subpopulations similarly point to lineage‐restricted and progesterone‐driven protein changes (Fig 3; Casey et al, 2018).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "From fetal mammary stem cells to the adult gland under defined hormone settings, these bodies of work provide a foundation for the discovery of novel chemopreventive agents using a systems approach to mammary cell biology (Fig 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This overarching workflow is depicted in Fig 4.Open questions\nIn the upcoming years, new approaches to breast cancer prevention are bound to flourish.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The ability to pre‐emptively identify women at increased risk for breast cancer is constantly evolving, with an expanding and better‐defined patient pool eligible for chemoprevention, whereas management and risk reduction options are lagging (Fig 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Overall, leveraging the potent influence of progesterone and its effects on mammary stem/progenitors, an anti‐progestin approach for prevention offers promise (Fig 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Ulipristal acetate is a selective progesterone receptor modulator, and denosumab is an anti‐RANKL agent. (B) Schematic of key mitogenic paracrine effectors downstream of progesterone in the breast, some of which may prove effective as targets in future breast cancer chemoprevention strategies.Progesterone's paracrine effectors\nWe now know that progesterone acts upon the ER+PR+ cells, which orchestrates a surge of potent paracrine effectors that in turn stimulate proliferation of the ER−PR− progenitor populations (Lydon et al, 1995; Humphreys et al, 1997; Brisken et al, 1998; Joshi et al, 2012; summarized in Fig 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Proteomic landscapes of murine mammary subpopulations similarly point to lineage‐restricted and progesterone‐driven protein changes (Fig 3; Casey et al, 2018).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "From fetal mammary stem cells to the adult gland under defined hormone settings, these bodies of work provide a foundation for the discovery of novel chemopreventive agents using a systems approach to mammary cell biology (Fig 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This overarching workflow is depicted in Fig 4.Open questions\nIn the upcoming years, new approaches to breast cancer prevention are bound to flourish.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The ability to pre‐emptively identify women at increased risk for breast cancer is constantly evolving, with an expanding and better‐defined patient pool eligible for chemoprevention, whereas management and risk reduction options are lagging (Fig 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Overall, leveraging the potent influence of progesterone and its effects on mammary stem/progenitors, an anti‐progestin approach for prevention offers promise (Fig 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Ulipristal acetate is a selective progesterone receptor modulator, and denosumab is an anti‐RANKL agent. (B) Schematic of key mitogenic paracrine effectors downstream of progesterone in the breast, some of which may prove effective as targets in future breast cancer chemoprevention strategies.Progesterone's paracrine effectors\nWe now know that progesterone acts upon the ER+PR+ cells, which orchestrates a surge of potent paracrine effectors that in turn stimulate proliferation of the ER−PR− progenitor populations (Lydon et al, 1995; Humphreys et al, 1997; Brisken et al, 1998; Joshi et al, 2012; summarized in Fig 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Proteomic landscapes of murine mammary subpopulations similarly point to lineage‐restricted and progesterone‐driven protein changes (Fig 3; Casey et al, 2018).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "From fetal mammary stem cells to the adult gland under defined hormone settings, these bodies of work provide a foundation for the discovery of novel chemopreventive agents using a systems approach to mammary cell biology (Fig 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This overarching workflow is depicted in Fig 4.Open questions\nIn the upcoming years, new approaches to breast cancer prevention are bound to flourish.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The ability to pre‐emptively identify women at increased risk for breast cancer is constantly evolving, with an expanding and better‐defined patient pool eligible for chemoprevention, whereas management and risk reduction options are lagging (Fig 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Overall, leveraging the potent influence of progesterone and its effects on mammary stem/progenitors, an anti‐progestin approach for prevention offers promise (Fig 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Ulipristal acetate is a selective progesterone receptor modulator, and denosumab is an anti‐RANKL agent. (B) Schematic of key mitogenic paracrine effectors downstream of progesterone in the breast, some of which may prove effective as targets in future breast cancer chemoprevention strategies.Progesterone's paracrine effectors\nWe now know that progesterone acts upon the ER+PR+ cells, which orchestrates a surge of potent paracrine effectors that in turn stimulate proliferation of the ER−PR− progenitor populations (Lydon et al, 1995; Humphreys et al, 1997; Brisken et al, 1998; Joshi et al, 2012; summarized in Fig 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Proteomic landscapes of murine mammary subpopulations similarly point to lineage‐restricted and progesterone‐driven protein changes (Fig 3; Casey et al, 2018).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "From fetal mammary stem cells to the adult gland under defined hormone settings, these bodies of work provide a foundation for the discovery of novel chemopreventive agents using a systems approach to mammary cell biology (Fig 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This overarching workflow is depicted in Fig 4.Open questions\nIn the upcoming years, new approaches to breast cancer prevention are bound to flourish.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The ability to pre‐emptively identify women at increased risk for breast cancer is constantly evolving, with an expanding and better‐defined patient pool eligible for chemoprevention, whereas management and risk reduction options are lagging (Fig 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Overall, leveraging the potent influence of progesterone and its effects on mammary stem/progenitors, an anti‐progestin approach for prevention offers promise (Fig 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Ulipristal acetate is a selective progesterone receptor modulator, and denosumab is an anti‐RANKL agent. (B) Schematic of key mitogenic paracrine effectors downstream of progesterone in the breast, some of which may prove effective as targets in future breast cancer chemoprevention strategies.Progesterone's paracrine effectors\nWe now know that progesterone acts upon the ER+PR+ cells, which orchestrates a surge of potent paracrine effectors that in turn stimulate proliferation of the ER−PR− progenitor populations (Lydon et al, 1995; Humphreys et al, 1997; Brisken et al, 1998; Joshi et al, 2012; summarized in Fig 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Proteomic landscapes of murine mammary subpopulations similarly point to lineage‐restricted and progesterone‐driven protein changes (Fig 3; Casey et al, 2018).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "From fetal mammary stem cells to the adult gland under defined hormone settings, these bodies of work provide a foundation for the discovery of novel chemopreventive agents using a systems approach to mammary cell biology (Fig 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This overarching workflow is depicted in Fig 4.Open questions\nIn the upcoming years, new approaches to breast cancer prevention are bound to flourish.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The ability to pre‐emptively identify women at increased risk for breast cancer is constantly evolving, with an expanding and better‐defined patient pool eligible for chemoprevention, whereas management and risk reduction options are lagging (Fig 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Overall, leveraging the potent influence of progesterone and its effects on mammary stem/progenitors, an anti‐progestin approach for prevention offers promise (Fig 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Ulipristal acetate is a selective progesterone receptor modulator, and denosumab is an anti‐RANKL agent. (B) Schematic of key mitogenic paracrine effectors downstream of progesterone in the breast, some of which may prove effective as targets in future breast cancer chemoprevention strategies.Progesterone's paracrine effectors\nWe now know that progesterone acts upon the ER+PR+ cells, which orchestrates a surge of potent paracrine effectors that in turn stimulate proliferation of the ER−PR− progenitor populations (Lydon et al, 1995; Humphreys et al, 1997; Brisken et al, 1998; Joshi et al, 2012; summarized in Fig 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Proteomic landscapes of murine mammary subpopulations similarly point to lineage‐restricted and progesterone‐driven protein changes (Fig 3; Casey et al, 2018).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "From fetal mammary stem cells to the adult gland under defined hormone settings, these bodies of work provide a foundation for the discovery of novel chemopreventive agents using a systems approach to mammary cell biology (Fig 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This overarching workflow is depicted in Fig 4.Open questions\nIn the upcoming years, new approaches to breast cancer prevention are bound to flourish.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The ability to pre‐emptively identify women at increased risk for breast cancer is constantly evolving, with an expanding and better‐defined patient pool eligible for chemoprevention, whereas management and risk reduction options are lagging (Fig 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Overall, leveraging the potent influence of progesterone and its effects on mammary stem/progenitors, an anti‐progestin approach for prevention offers promise (Fig 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Ulipristal acetate is a selective progesterone receptor modulator, and denosumab is an anti‐RANKL agent. (B) Schematic of key mitogenic paracrine effectors downstream of progesterone in the breast, some of which may prove effective as targets in future breast cancer chemoprevention strategies.Progesterone's paracrine effectors\nWe now know that progesterone acts upon the ER+PR+ cells, which orchestrates a surge of potent paracrine effectors that in turn stimulate proliferation of the ER−PR− progenitor populations (Lydon et al, 1995; Humphreys et al, 1997; Brisken et al, 1998; Joshi et al, 2012; summarized in Fig 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Proteomic landscapes of murine mammary subpopulations similarly point to lineage‐restricted and progesterone‐driven protein changes (Fig 3; Casey et al, 2018).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "From fetal mammary stem cells to the adult gland under defined hormone settings, these bodies of work provide a foundation for the discovery of novel chemopreventive agents using a systems approach to mammary cell biology (Fig 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This overarching workflow is depicted in Fig 4.Open questions\nIn the upcoming years, new approaches to breast cancer prevention are bound to flourish.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The ability to pre‐emptively identify women at increased risk for breast cancer is constantly evolving, with an expanding and better‐defined patient pool eligible for chemoprevention, whereas management and risk reduction options are lagging (Fig 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Overall, leveraging the potent influence of progesterone and its effects on mammary stem/progenitors, an anti‐progestin approach for prevention offers promise (Fig 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Ulipristal acetate is a selective progesterone receptor modulator, and denosumab is an anti‐RANKL agent. (B) Schematic of key mitogenic paracrine effectors downstream of progesterone in the breast, some of which may prove effective as targets in future breast cancer chemoprevention strategies.Progesterone's paracrine effectors\nWe now know that progesterone acts upon the ER+PR+ cells, which orchestrates a surge of potent paracrine effectors that in turn stimulate proliferation of the ER−PR− progenitor populations (Lydon et al, 1995; Humphreys et al, 1997; Brisken et al, 1998; Joshi et al, 2012; summarized in Fig 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Proteomic landscapes of murine mammary subpopulations similarly point to lineage‐restricted and progesterone‐driven protein changes (Fig 3; Casey et al, 2018).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "From fetal mammary stem cells to the adult gland under defined hormone settings, these bodies of work provide a foundation for the discovery of novel chemopreventive agents using a systems approach to mammary cell biology (Fig 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This overarching workflow is depicted in Fig 4.Open questions\nIn the upcoming years, new approaches to breast cancer prevention are bound to flourish.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The ability to pre‐emptively identify women at increased risk for breast cancer is constantly evolving, with an expanding and better‐defined patient pool eligible for chemoprevention, whereas management and risk reduction options are lagging (Fig 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The ability to pre‐emptively identify women at increased risk for breast cancer is constantly evolving, with an expanding and better‐defined patient pool eligible for chemoprevention, whereas management and risk reduction options are lagging (Fig 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The ability to pre‐emptively identify women at increased risk for breast cancer is constantly evolving, with an expanding and better‐defined patient pool eligible for chemoprevention, whereas management and risk reduction options are lagging (Fig 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Overall, leveraging the potent influence of progesterone and its effects on mammary stem/progenitors, an anti‐progestin approach for prevention offers promise (Fig 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Ulipristal acetate is a selective progesterone receptor modulator, and denosumab is an anti‐RANKL agent. (B) Schematic of key mitogenic paracrine effectors downstream of progesterone in the breast, some of which may prove effective as targets in future breast cancer chemoprevention strategies.Progesterone's paracrine effectors\nWe now know that progesterone acts upon the ER+PR+ cells, which orchestrates a surge of potent paracrine effectors that in turn stimulate proliferation of the ER−PR− progenitor populations (Lydon et al, 1995; Humphreys et al, 1997; Brisken et al, 1998; Joshi et al, 2012; summarized in Fig 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Overall, leveraging the potent influence of progesterone and its effects on mammary stem/progenitors, an anti‐progestin approach for prevention offers promise (Fig 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Overall, leveraging the potent influence of progesterone and its effects on mammary stem/progenitors, an anti‐progestin approach for prevention offers promise (Fig 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Progesterone's paracrine effectors\nWe now know that progesterone acts upon the ER+PR+ cells, which orchestrates a surge of potent paracrine effectors that in turn stimulate proliferation of the ER−PR− progenitor populations (Lydon et al, 1995; Humphreys et al, 1997; Brisken et al, 1998; Joshi et al, 2012; summarized in Fig 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "We now know that progesterone acts upon the ER+PR+ cells, which orchestrates a surge of potent paracrine effectors that in turn stimulate proliferation of the ER−PR− progenitor populations (Lydon et al, 1995; Humphreys et al, 1997; Brisken et al, 1998; Joshi et al, 2012; summarized in Fig 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Proteomic landscapes of murine mammary subpopulations similarly point to lineage‐restricted and progesterone‐driven protein changes (Fig 3; Casey et al, 2018).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Proteomic landscapes of murine mammary subpopulations similarly point to lineage‐restricted and progesterone‐driven protein changes (Fig 3; Casey et al, 2018).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Proteomic landscapes of murine mammary subpopulations similarly point to lineage‐restricted and progesterone‐driven protein changes (Fig 3; Casey et al, 2018).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "From fetal mammary stem cells to the adult gland under defined hormone settings, these bodies of work provide a foundation for the discovery of novel chemopreventive agents using a systems approach to mammary cell biology (Fig 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This overarching workflow is depicted in Fig 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "From fetal mammary stem cells to the adult gland under defined hormone settings, these bodies of work provide a foundation for the discovery of novel chemopreventive agents using a systems approach to mammary cell biology (Fig 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This overarching workflow is depicted in Fig 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  }
]